The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration containing a therapeutically effective amount of Ivabradine HCl polymorph IV or δ in combination with moisture protective excipients and/or low or non- hygroscopic anhydrous excipients in order to avoid polymorphic transformation of the active ingredient. It also relates to a process for the preparation thereof.
